• Je něco špatně v tomto záznamu ?

Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia

P. Baliakas, T. Moysiadis, A. Hadzidimitriou, A. Xochelli, S. Jeromin, A. Agathangelidis, M. Mattsson, LA. Sutton, E. Minga, L. Scarfò, D. Rossi, Z. Davis, N. Villamor, H. Parker, J. Kotaskova, E. Stalika, K. Plevova, L. Mansouri, D. Cortese, A....

. 2019 ; 104 (2) : 360-369. [pub] 20180927

Jazyk angličtina Země Itálie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20022899

Chronic lymphocytic leukemia (CLL) patients with differential somatic hypermutation status of the immunoglobulin heavy variable genes, namely mutated or unmutated, display fundamental clinico-biological differences. Considering this, we assessed prognosis separately within mutated (M-CLL) and unmutated (U-CLL) CLL in 3015 patients, hypothesizing that the relative significance of relevant indicators may differ between these two categories. Within Binet A M-CLL patients, besides TP53 abnormalities, trisomy 12 and stereotyped subset #2 membership were equivalently associated with the shortest time-to-first-treatment and a treatment probability at five and ten years after diagnosis of 40% and 55%, respectively; the remaining cases exhibited 5-year and 10-year treatment probability of 12% and 25%, respectively. Within Binet A U-CLL patients, besides TP53 abnormalities, del(11q) and/or SF3B1 mutations were associated with the shortest time-to-first-treatment (5- and 10-year treatment probability: 78% and 98%, respectively); in the remaining cases, males had a significantly worse prognosis than females. In conclusion, the relative weight of indicators that can accurately risk stratify early-stage CLL patients differs depending on the somatic hypermutation status of the immunoglobulin heavy variable genes of each patient. This finding highlights the fact that compartmentalized approaches based on immunogenetic features are necessary to refine and tailor prognostication in CLL.

Cancer Genomics Academic Unit of Cancer Sciences Cancer Research UK Centre and Experimental Cancer Medicine Centre Faculty of Medicine University of Southampton UK

Central European Institute of Technology Masaryk University and University Hospital Brno Czech Republic

Department of Haematology Royal Bournemouth Hospital UK

Department of Hemato Oncology Belfast City Hospital UK

Department of Immunology Genetics and Pathology Science for Life Laboratory Uppsala University Sweden

Department of Immunology Genetics and Pathology Science for Life Laboratory Uppsala University Sweden Institute of Applied Biosciences Center for Research and Technology Hellas Thessaloniki Greece

Department of Medicine Solna Clinical Epidemiology Unit Karolinska Institutet Stockholm Sweden

Department of Molecular Medicine and Surgery Karolinska Institutet Stockholm Sweden

Division of Experimental Oncology IRCCS Istituto Scientifico San Raffaele and Università Vita Salute San Raffaele Milan Italy

Division of Hematology Department of Translational Medicine Amedeo Avogadro University of Eastern Piedmont Novara Italy

Hematology Department and HCT Unit G Papanicolaou Hospital Thessaloniki Greece

Hematology Department Hospital Clinic Barcelona Spain

Hematology Department Nikea General Hospital Pireaus Greece

Hemopathology Unit Hospital Clinic Barcelona Spain

Hemopathology Unit Hospital Clinic Barcelona Spain Department of Pathology University of Barcelona Spain

Institute of Applied Biosciences Center for Research and Technology Hellas Thessaloniki Greece

Institute of Applied Biosciences Center for Research and Technology Hellas Thessaloniki Greece Hematology Department and HCT Unit G Papanicolaou Hospital Thessaloniki Greece

Lund University and Hospital Department of Hematology Lund Stem Cell Center Sweden

MLL Munich Leukemia Laboratory Munich Germany

Oncology Institute of Southern Switzerland Bellinzona Switzerland

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20022899
003      
CZ-PrNML
005      
20201214124940.0
007      
ta
008      
201125s2019 it f 000 0|eng||
009      
AR
024    7_
$a 10.3324/haematol.2018.195032 $2 doi
035    __
$a (PubMed)30262567
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Baliakas, Panagiotis $u Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
245    10
$a Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia / $c P. Baliakas, T. Moysiadis, A. Hadzidimitriou, A. Xochelli, S. Jeromin, A. Agathangelidis, M. Mattsson, LA. Sutton, E. Minga, L. Scarfò, D. Rossi, Z. Davis, N. Villamor, H. Parker, J. Kotaskova, E. Stalika, K. Plevova, L. Mansouri, D. Cortese, A. Navarro, J. Delgado, M. Larrayoz, E. Young, A. Anagnostopoulos, KE. Smedby, G. Juliusson, O. Sheehy, M. Catherwood, JC. Strefford, N. Stavroyianni, C. Belessi, S. Pospisilova, D. Oscier, G. Gaidano, E. Campo, C. Haferlach, P. Ghia, R. Rosenquist, K. Stamatopoulos, European Research Initiative on CLL (ERIC),
520    9_
$a Chronic lymphocytic leukemia (CLL) patients with differential somatic hypermutation status of the immunoglobulin heavy variable genes, namely mutated or unmutated, display fundamental clinico-biological differences. Considering this, we assessed prognosis separately within mutated (M-CLL) and unmutated (U-CLL) CLL in 3015 patients, hypothesizing that the relative significance of relevant indicators may differ between these two categories. Within Binet A M-CLL patients, besides TP53 abnormalities, trisomy 12 and stereotyped subset #2 membership were equivalently associated with the shortest time-to-first-treatment and a treatment probability at five and ten years after diagnosis of 40% and 55%, respectively; the remaining cases exhibited 5-year and 10-year treatment probability of 12% and 25%, respectively. Within Binet A U-CLL patients, besides TP53 abnormalities, del(11q) and/or SF3B1 mutations were associated with the shortest time-to-first-treatment (5- and 10-year treatment probability: 78% and 98%, respectively); in the remaining cases, males had a significantly worse prognosis than females. In conclusion, the relative weight of indicators that can accurately risk stratify early-stage CLL patients differs depending on the somatic hypermutation status of the immunoglobulin heavy variable genes of each patient. This finding highlights the fact that compartmentalized approaches based on immunogenetic features are necessary to refine and tailor prognostication in CLL.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    12
$a nádorové biomarkery $7 D014408
650    _2
$a chromozomální aberace $7 D002869
650    12
$a náchylnost k nemoci $7 D004198
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a imunogenetika $7 D007125
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a chronická lymfatická leukemie $x etiologie $x mortalita $x patologie $x terapie $7 D015451
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mutace $7 D009154
650    _2
$a staging nádorů $7 D009367
650    _2
$a prognóza $7 D011379
650    _2
$a čas zasáhnout při rozvinutí nemoci $7 D061665
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Moysiadis, Theodoros $u Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece.
700    1_
$a Hadzidimitriou, Anastasia $u Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden. Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece.
700    1_
$a Xochelli, Aliki $u Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden. Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece.
700    1_
$a Jeromin, Sabine $u MLL Munich Leukemia Laboratory, Munich, Germany.
700    1_
$a Agathangelidis, Andreas $u Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece.
700    1_
$a Mattsson, Mattias $u Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
700    1_
$a Sutton, Lesley-Ann $u Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
700    1_
$a Minga, Eva $u Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece.
700    1_
$a Scarfò, Lydia $u Division of Experimental Oncology, IRCCS Istituto Scientifico San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy.
700    1_
$a Rossi, Davide $u Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
700    1_
$a Davis, Zadie $u Department of Haematology, Royal Bournemouth Hospital, UK.
700    1_
$a Villamor, Neus $u Hemopathology Unit, Hospital Clinic, Barcelona, Spain.
700    1_
$a Parker, Helen $u Cancer Genomics, Academic Unit of Cancer Sciences, Cancer Research UK Centre and Experimental Cancer Medicine Centre, Faculty of Medicine, University of Southampton, UK.
700    1_
$a Kotaskova, Jana $u Central European Institute of Technology, Masaryk University and University Hospital Brno, Czech Republic.
700    1_
$a Stalika, Evangelia $u Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece. Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.
700    1_
$a Plevova, Karla $u Central European Institute of Technology, Masaryk University and University Hospital Brno, Czech Republic.
700    1_
$a Mansouri, Larry $u Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
700    1_
$a Cortese, Diego $u Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
700    1_
$a Navarro, Alba $u Hemopathology Unit, Hospital Clinic, Barcelona, Spain.
700    1_
$a Delgado, Julio $u Hematology Department, Hospital Clinic, Barcelona, Spain.
700    1_
$a Larrayoz, Marta $u Cancer Genomics, Academic Unit of Cancer Sciences, Cancer Research UK Centre and Experimental Cancer Medicine Centre, Faculty of Medicine, University of Southampton, UK.
700    1_
$a Young, Emma $u Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
700    1_
$a Anagnostopoulos, Achilles $u Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.
700    1_
$a Smedby, Karin E $u Department of Medicine, Solna, Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden.
700    1_
$a Juliusson, Gunnar $u Lund University and Hospital Department of Hematology, Lund Stem Cell Center, Sweden.
700    1_
$a Sheehy, Oonagh $u Department of Hemato-Oncology, Belfast City Hospital, UK.
700    1_
$a Catherwood, Mark $u Department of Hemato-Oncology, Belfast City Hospital, UK.
700    1_
$a Strefford, Jonathan C $u Cancer Genomics, Academic Unit of Cancer Sciences, Cancer Research UK Centre and Experimental Cancer Medicine Centre, Faculty of Medicine, University of Southampton, UK.
700    1_
$a Stavroyianni, Niki $u Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.
700    1_
$a Belessi, Chrysoula $u Hematology Department, Nikea General Hospital, Pireaus, Greece.
700    1_
$a Pospisilova, Sarka $u Central European Institute of Technology, Masaryk University and University Hospital Brno, Czech Republic.
700    1_
$a Oscier, David $u Department of Haematology, Royal Bournemouth Hospital, UK.
700    1_
$a Gaidano, Gianluca $u Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy.
700    1_
$a Campo, Elias $u Hemopathology Unit, Hospital Clinic, Barcelona, Spain. Department of Pathology, University of Barcelona, Spain.
700    1_
$a Haferlach, Claudia $u MLL Munich Leukemia Laboratory, Munich, Germany.
700    1_
$a Ghia, Paolo $u Division of Experimental Oncology, IRCCS Istituto Scientifico San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy.
700    1_
$a Rosenquist, Richard $u Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
700    1_
$a Stamatopoulos, Kostas $u Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden kostas.stamatopoulos@gmail.com. Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece.
710    2_
$a European Research Initiative on CLL (ERIC)
773    0_
$w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 104, č. 2 (2019), s. 360-369
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30262567 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214124940 $b ABA008
999    __
$a ok $b bmc $g 1595218 $s 1113575
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 104 $c 2 $d 360-369 $e 20180927 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace